Stem-cell therapy

ViaCyte to Present at the Jefferies Virtual Healthcare Conference

Thursday, May 28, 2020 - 2:00pm

SAN DIEGO, May 28, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9.

Key Points: 
  • SAN DIEGO, May 28, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9.
  • ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement.
  • During the presentation, Dr. Laikind will discuss ViaCyte's leadership in discovering and developing novel cell replacement therapies to treat human diseases.
  • With CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 pluripotent stem cell line.

Frequency Therapeutics to Present at Upcoming Investor Conferences

Wednesday, May 27, 2020 - 1:00pm

A replay of each presentation will be posted on the Frequency website for at least 30 days following each event.

Key Points: 
  • A replay of each presentation will be posted on the Frequency website for at least 30 days following each event.
  • Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases.
  • The Companys progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies.
  • The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.

Insights into North America's Biobanks Market 2020, Featuring Key Player Profiles Including Atlanta Biologicals Inc., BioLifeSolutions Inc. and Thermo Fisher Scientific Inc.

Friday, May 22, 2020 - 10:15pm

Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.

Key Points: 
  • Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.
  • Several advancements have been made in regenerative medicine through stem cell technology over the past decade.
  • Thus, it has become one of the vital treatment methods for diseases, such as Alzheimer's, diabetes, cancer, and rare genetic diseases.
  • In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved in Biobanks.

R3 Stem Cell International Now Offering Enhanced Autism Stem Cell Program in Mexico

Monday, May 18, 2020 - 5:00am

SCOTTSDALE, Ariz., May 18, 2020 /PRNewswire-PRWeb/ -- R3 Stem Cell International is now offering an enhanced autism stem cell therapy program at its Tijuana regenerative clinic.

Key Points: 
  • SCOTTSDALE, Ariz., May 18, 2020 /PRNewswire-PRWeb/ -- R3 Stem Cell International is now offering an enhanced autism stem cell therapy program at its Tijuana regenerative clinic.
  • R3 Stem Cell International's enhanced program provides umbilical cord derived stem cell therapy for patients, with total cell counts for the treatment ranging between 90 million up to 200 million live stem cells.
  • As with all R3 Stem Cell International procedures, R3 takes care of concierge escort transportation from San Diego to the clinic, which is only 20 minutes from the SD International Airport.
  • About R3 Stem Cell International: After 14,000 stem cell procedures in the US, R3 opened R3 Stem Cell International.

Analysis on Impact of COVID-19-Stem Cell Therapy Market 2020-2024 | Increase in Awareness of Stem Cell Therapy to Boost Growth | Technavio

Monday, May 18, 2020 - 8:45am

Our stem cell therapy market report covers the following areas:

Key Points: 
  • Our stem cell therapy market report covers the following areas:
    This study identifies limited number of FDA-approved stem cell therapies as one of the prime reasons driving the stem cell therapy market growth during the next few years.
  • Stem Cell Therapy Market 2020-2024: Vendor Analysis
    We provide a detailed analysis of vendors operating in the stem cell therapy market, including some of the vendors such as Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp.
  • Backed with competitive intelligence and benchmarking, our research reports on the stem cell therapy market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Stem Cell Therapy Market 2020-2024: Key Highlights

Stem Cells | Worldwide Pipeline Landscape Assessment 2020: Clinical Trial Stages, Drug Mechanism Classes, Companies Involved

Wednesday, May 13, 2020 - 11:30pm

This research report provides the most up-to-date information on key pipeline products in the global Stem Cells market.

Key Points: 
  • This research report provides the most up-to-date information on key pipeline products in the global Stem Cells market.
  • It covers emerging therapies for Stem Cells in active clinical development stages including early and late stage clinical trials.
  • The report provides Stem Cells pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
  • The report provides Stem Cells pipeline products by their dominant mechanism of action.

Stem Cell Therapy | Global Industry Review 2015-2019 and Forecast to 2025

Wednesday, May 13, 2020 - 8:45pm

The Global Stem Cell Therapy Market is expected to grow at a formidable rate of around 12% during the forecast period.

Key Points: 
  • The Global Stem Cell Therapy Market is expected to grow at a formidable rate of around 12% during the forecast period.
  • Additionally, increase in number of stem cell banks and growing investments by the government and private organizations for the development of stem cell preservation infrastructure is further propelling the market across the globe.
  • The allogenic type segment is expected to register the highest growth during forecast period attributable to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, growing number of clinical trials related to allogeneic stem cell therapies, among others.
  • Regionally, the stem cell therapy market has been segmented into various regions namely Asia-Pacific, North America, South America, Europe, and Middle East & Africa.

Global Stem Cell Therapy Market Forecast & Opportunities, 2025 - ResearchAndMarkets.com

Wednesday, May 13, 2020 - 4:15pm

The "Global Stem Cell Therapy Market By Type (Allogeneic, Autologous, Syngeneic), By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs, Others), By Application, By End Users, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Stem Cell Therapy Market By Type (Allogeneic, Autologous, Syngeneic), By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs, Others), By Application, By End Users, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.
  • The Global Stem Cell Therapy Market is expected to grow at a formidable rate of around 12% during the forecast period.
  • Additionally, increase in number of stem cell banks and growing investments by the government and private organizations for the development of stem cell preservation infrastructure is further propelling the market across the globe.
  • Regionally, the stem cell therapy market has been segmented into various regions namely Asia-Pacific, North America, South America, Europe, and Middle East & Africa.

Asymmetrex Presents Benefits of Stem Cell Counting at Clinical Trial Supply Conference

Wednesday, May 13, 2020 - 8:00am

BOSTON, May 13, 2020 /PRNewswire-PRWeb/ --On May 12, the director of stem cell biotechnology company Asymmetrex continued to demonstrate the reach of his company's tissue stem cell counting technology into all aspects of the stem cell regenerative medicine industry.

Key Points: 
  • BOSTON, May 13, 2020 /PRNewswire-PRWeb/ --On May 12, the director of stem cell biotechnology company Asymmetrex continued to demonstrate the reach of his company's tissue stem cell counting technology into all aspects of the stem cell regenerative medicine industry.
  • Speaking online in Arena International's Clinical Trial Supply 2020 conference , James Sherley, M.D., Ph.D. outlined how achieving a more effective supply chain for stem-gene therapy clinical trials will require the industry to advance to certification of the stem cell-specific properties of transported cell and gene therapies.
  • In his clinical trial supply presentation, he related the importance of the same care in ensuring that the potency and quality of stem cell treatments are preserved during transport for supply of stem-gene clinical trials.
  • Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the "AlphaSTEM Test") for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Stem Cells Pipeline Highlights 2020: Key Pipeline Products, Emerging Therapies, Opportunities, and Players - ResearchAndMarkets.com

Tuesday, May 12, 2020 - 1:20pm

This research report provides the most up-to-date information on key pipeline products in the global Stem Cells market.

Key Points: 
  • This research report provides the most up-to-date information on key pipeline products in the global Stem Cells market.
  • It covers emerging therapies for Stem Cells in active clinical development stages including early and late stage clinical trials.
  • The report provides Stem Cells pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
  • The report provides Stem Cells pipeline products by their dominant mechanism of action.